UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025...
Day: April 27, 2025
Best Male Enhancement Pills & Libido Booster For Men: (Penis Enlargement Pills) Over The Counter Best ED Pills Non Prescription – By Performer 8
More than 50% of men now face erectile dysfunction after the age of 40. In a few cases, men in...
2025 (Spring) Pharmaceutical Machinery Exposition Concludes Successfully
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition &...
Best Legal Steroids For Muscle Growth: Top Anabolic Steroids Alternatives For (Bulking & Bodybuilding) That Really Work – By Crazy Bulk
After six months of research on the ingredients and thousands of feedback from real consumers, we can safely say that...
Three-Year Data of Zenflow’s Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT InterventionsSOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE)...
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%...
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder...
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of...
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced...
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates...